Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 20-001725
NCT ID: NCT03689595
Sponsor Protocol Number: 18-370
About this study
The purpose of this study is to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Age ≥ 45 and ≤ 75 years old AND
- AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström’s Macroglobulinemia, or another blood cancer.
- For participants with a strong family history (2 relatives with blood cancers, their first- and second-degree relatives will be allowed to participate if 18 years or older.
Exclusion Criteria:
- Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy.
- Persons diagnoses with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström’s Macroglobulinemia.
- First degree relatives would not need to be identified by the participant.
- We will include all special populations who fall within the eligible high-risk age range, ≥ 40 and ≤ 75 including adults unable to consent, pregnant women, and prisoners. These populations will not be excluded as this is a non-therapeutic study.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Rochester, Minn.
Mayo Clinic principal investigator Prashant Kapoor, M.D. |
Closed for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
Contact Us-
|
More information
Publications
Publications are currently not available